Abstract
In Japan, the comprehensive genomic profiling (CGP)tests were covered by insurance in June 2019, and more than 23,000 cases have been tested so far. On the other hand, only 8.1% of patients were reported to have received treatment, suggesting that the benefits of CGP test may not be fully utilized. In Japan, CGP tests are indicated for patients with solid tumors who have no standard treatment or who failed all standard treatment (including those expected to failure). This situation has been pointed out that access to drugs may be poor due to the timing of last-line treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
